Advertisement
Canada markets closed
  • S&P/TSX

    22,851.17
    -144.22 (-0.63%)
     
  • S&P 500

    5,588.27
    -78.93 (-1.39%)
     
  • DOW

    41,198.08
    +243.60 (+0.59%)
     
  • CAD/USD

    0.7310
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    83.10
    +2.34 (+2.90%)
     
  • Bitcoin CAD

    87,836.32
    -726.05 (-0.82%)
     
  • CMC Crypto 200

    1,339.45
    -2.88 (-0.21%)
     
  • GOLD FUTURES

    2,463.10
    -4.70 (-0.19%)
     
  • RUSSELL 2000

    2,239.67
    -24.00 (-1.06%)
     
  • 10-Yr Bond

    4.1460
    -0.0210 (-0.50%)
     
  • NASDAQ futures

    20,016.75
    -581.25 (-2.82%)
     
  • VOLATILITY

    14.48
    +1.29 (+9.78%)
     
  • FTSE

    8,187.46
    +22.56 (+0.28%)
     
  • NIKKEI 225

    41,097.69
    -177.39 (-0.43%)
     
  • CAD/EUR

    0.6678
    -0.0030 (-0.45%)
     

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval

Pfizer currently dominates the market for pneumococcal vaccines, which protect against bacterial infections that can cause pneumonia and meningitis, among other conditions. Merck, however, has been nipping at Pfizer’s heels for years. The company sells Vaxneuvance and Pneumovax 23, pneumococcal vaccines with combined 2023 revenue of $1.1 billion.